REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)

Inclusion Criteria: * Women aged 18 years and above * Confirmed cervical infection with HPV types 16 and/or 18 at screening * Cervical tissue specimen/slides provided to Study Pathology Adjudication Committee for diagnosis scheduled to be collected within 10 weeks prior to anticipated date of first dose of study drug * Confirmed histologic evidence of cervical HSIL at screening * Must be judged by Investigator to be an appropriate candidate for the protocol-specified procedure required at Week 36 * With respect to their reproductive capacity must be post-menopausal or surgically sterile or willing to use a contraceptive method with failure rate of less than 1% per year when used consistently and correctly from screening until Week 36 * Normal screening electrocardiogram (ECG) Exclusion Criteria: * Microscopic or gross evidence of adenocarcinoma-in-situ (AIS), high grade vulvar, vaginal, or anal intraepithelial neoplasia or invasive cancer in any histopathologic specimen at screening * Cervical lesion(s) that cannot be fully visualized on colposcopy * History of endocervical curettage (ECC) which showed cervical HSIL indeterminate, or insufficient for diagnosis * Treatment for cervical HSIL within 4 weeks prior to screening * Pregnant, breastfeeding or considering becoming pregnant during the study * History of previous therapeutic HPV vaccination * Immunosuppression as a result of underlying illness or treatment * Receipt of any non-study, non-live vaccine within 2 weeks o…